News
What type of asthma inhaler is right for you?
5+ day, 18+ hour ago (1746+ words) In the U. S. , 25 million people are affected by asthma. That's roughly 1 in 13 adults and children. Asthma can be mild or severe. Some people with asthma have symptoms every day. Others have symptoms that only kick in when they experience triggers. Since…...
Discussing Add-On Biologic Therapy for Patients With Moderate to Severe Asthma
2+ week, 5+ day ago (705+ words) For patients with moderate to severe asthma with uncontrolled disease, add-on biologic maintenance therapy such as dupilumab or tezepelumab may be appropriate. In this article, Amanda Michaud, DMSc, PA-C, AE-C, an allergy, asthma, and immunology specialist at Family Allergy and…...
Study suggests asthma LABA medications do not increase severity of food allergy reactions during oral food challenges
1+ mon, 1+ week ago (248+ words) DENVER -New research from National Jewish Health suggests that long-acting beta-agonists (LABAs), commonly used in combination asthma inhalers, are not associated with more severe reactions during oral food challenges in children with asthma and food allergy. The study was recently…...
Dupixent" (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
2+ week, 6+ day ago (684+ words) Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense…...
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13+ hour, 46+ min ago (207+ words) Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria In the US, the supplemental biologics license application for Dupixent has been accepted for review in certain children aged…...
Agomab Receives U. S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
2+ week, 4+ day ago (283+ words) Antwerp, Belgium, March 26, 2026 " Agomab Therapeutics NV (Nasdaq: AGMB) (Agomab), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U. S. Patent No. 12, 577, 230, covering the composition of matter of AGMB-447, to Agomab....
Just a Sniffle? Easy Ways to Spot Spring Allergies
4+ day, 10+ hour ago (269+ words) Between spring allergies and all the other viruses circulating, it can be hard to know which one you're dealing with, whether that's the flu or just a cold. An allergist from the Cleveland Clinic offers some advice. Between the common…...
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch
1+ mon, 5+ day ago (249+ words) Alkermes plc (ALKS) announced an update on their ongoing clinical study. The Brilliance NT1 Study 302 is a Phase 3 trial run by Alkermes, Inc. to test ALKS 2680 in adults with narcolepsy type 1. It aims to see if the drug can cut daytime…...
One breath at a time | IU Health trying to close the gap for respiratory therapists
22+ hour, 53+ min ago (387+ words) Dalin Hatch didn't expect he'd walk the halls of a hospital for his career. The soon-to-be college graduate already works as a respiratory therapist at Riley Hospital for Children. "I just went to the hospital a lot of times for…...
Are your spring allergies acting up? Try these easy, affordable expert-backed tips for quick relief
2+ week, 5+ day ago (649+ words) Are you sneezing, itching your eyes or feeling a bit congested? You have probably been hit with spring allergies. According to some experts, allergy sufferers may be dealing with symptoms for the long haul this year. "I feel like this…...